New Jersey is currently home to 1653 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Avalglucosidase Alfa Pregnancy Study
NCT05734521
Recruiting
This is a worldwide, descriptive safety study collecting data on women and their offspring exposed to avalglucosidase alfa during pregnancy and/or lactation, to assess the risks of avalglucsodiase alfa on pregnancy and maternal complications and adverse effects in the developing fetus, neonate, and infant. * Outcomes in exposed infants, including growth and development, will be assessed through at least the first year of life. * Data will be collected for approximately 10 years.
Gender:
FEMALE
Ages:
All
Trial Updated:
07/12/2024
Locations: Investigational site worldwide, Bridgewater, New Jersey
Conditions: Pompe Disease, Pregnancy
Register for Updates
Serious Game-based Interventions in Patients With Mild Cognitive Impairment Outside the Clinic
NCT04920123
Recruiting
This study will evaluate the therapeutic efficacy of Neuro-World cognitive training games (Woorisoft, S. Korea) in patients with mild cognitive impairment.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/12/2024
Locations: The State University of New Jersey, Rutgers, Newark, New Jersey
Conditions: Mild Cognitive Impairment
Register for Updates
PARADIGM: Amplatzer Valvular Plug for PVL Closure
NCT04489823
Recruiting
The Paradigm study is a prospective, multicenter, single arm study to demonstrate the safety and effectiveness of the Amplatzer Valvular Plug III (AVP III) as a treatment for clinically significant PVLs following surgical implant of a mechanical or biological heart valve implanted in the aortic or mitral position.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Paravalvular Aortic Regurgitation
Register for Updates
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
NCT03997370
Recruiting
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/11/2024
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Conditions: Malignant Solid Neoplasm
Register for Updates
Bimekizumab in Plaque Psoriasis
NCT06336343
Recruiting
The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, interleukins 17a and 17F), which are known to increase inflammation. This study will look at the effectiveness of bimekizumab in psoriasis patients that have failed previous therapies that target interleuk... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Windsor Dermatology - Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Plaque Psoriasis
Register for Updates
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
NCT04332874
Recruiting
The purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, delivered directly to the affected arm or leg using a technique called isolated limb infusion (ILI), is a safe treatment that can delay the time before your disease gets worse (progresses).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/10/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey
Conditions: Sarcoma, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma, Alveolar Soft Part Sarcoma
Register for Updates
Immunotherapy for Third Line Metastatic Colorectal Cancer
NCT04444622
Recruiting
This is a Phase IIB multi-site, open label study of a next generation immunotherapy for third-line MSI-S metastatic colorectal cancer using an "off-the-shelf", non-genetically manipulated living immune cell product (AlloStim) derived from the blood of healthy donors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2024
Locations: Summit Health, Florham Park, New Jersey
Conditions: Metastatic Colorectal Cancer
Register for Updates
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT05534438
Recruiting
The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. This combination of SBRT to a single metastatic site and usual drug therapy may prevent participants' cancer from worsening in other metastatic sites or spreading.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer
Register for Updates
Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
NCT05314738
Recruiting
Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/04/2024
Locations: Glaukos Investigative Site, Teaneck, New Jersey
Conditions: Progressive Keratoconus
Register for Updates
Germ Cell Tumor and Testicular Tumor DNA Registry
NCT02099734
Recruiting
This study is being done to create a registry to help us learn more about germ cell tumors (GCT) and other testicular tumors. The registry will include people with these tumors and also relatives and unrelated people without these tumors. This study will help us learn more about the prevention, diagnosis, treatment and outcome of these tumors. Studying relatives of patients and people unrelated to patients with GCT and other testicular tumors will help us understand why some people get these tum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2024
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Conditions: Germ Cell Tumor, Testicular Tumor
Register for Updates
Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
NCT05424029
Recruiting
The purpose of this study is to find out if fluid rinsed from peoples' airways (bronchial washing samples) during routine surgery to remove (resect) their non-small cell lung cancer (NSCLC) tumors contains enough vesicles to do testing that may help the researchers learn more about their NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352
Recruiting
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Englewood Health, Englewood, New Jersey
Conditions: Endometrial Cancer
Register for Updates